Off-Label Dissemination Occurring Without FDA Okay After Feb. 16 WLF Ruling
This article was originally published in The Gray Sheet
Executive Summary
Medical device and pharmaceutical firms that choose to aggressively disseminate off-label information following a recent court ruling in Washington Legal Foundation v. FDA are at a higher risk for product liability claims, Washington attorney Alan Bennett, Fox Bennett and Turner, cautioned March 3 at a WLF-sponsored press briefing.
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.